Pharmacogenetics of naltrexone in Asian Americans: A randomized placebo-controlled laboratory study

Neuropsychopharmacology

Volumn 37, Issue 2, 2012, Pages 445-455

  Ray, Lara A ^a   Bujarski, Spencer ^a   Chin, Pauline F ^a   Miotto, Karen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

alcoholism; Asn40Asp; naltrexone; OPRM1; pharmacogenetics; subjective intoxication

Indexed keywords

ALCOHOL; ALCOHOL DEHYDROGENASE; ALCOHOL DEHYDROGENASE 1B; ALDEHYDE DEHYDROGENASE ISOENZYME 2; ASPARAGINE; ASPARTIC ACID; CORTICOTROPIN; HYDROCORTISONE; MU OPIATE RECEPTOR; NALTREXONE; PLACEBO; RIBOFLAVIN; UNCLASSIFIED DRUG;

ADULT; ALCOHOL INTOXICATION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; ASIAN AMERICAN; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GENE DOSAGE; GENE FREQUENCY; GENOTYPE; HELP SEEKING BEHAVIOR; HOMOZYGOTE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; PATIENT COMPLIANCE; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDER; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

ADRENOCORTICOTROPIC HORMONE; ADULT; ALCOHOL DEHYDROGENASE; ALCOHOLIC INTOXICATION; ALCOHOLISM; ALDEHYDE DEHYDROGENASE; ALLELES; ASIAN AMERICANS; BEHAVIOR, ADDICTIVE; DOUBLE-BLIND METHOD; ETHANOL; FEMALE; GENOTYPE; HUMANS; HYDROCORTISONE; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU;

EID: 84856024783     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.192     Document Type: Article

References (88)

1. Allen JP, Litten RZ, Fertig JB, Babor T (1997). A review of research on the Alcohol Use Disorders Identification Test (AUDIT). Alcohol Clin Exp Res 21: 613-619. (Pubitemid 27272786)
2. Anton RF, Drobes DJ, Voronin K, Durazo-Avizu R, Moak D (2004). Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl) 173: 32-40. (Pubitemid 38591144)
3. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK (1999). Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebocontrolled trial. Am J Psychiatry 156: 1758-1764. (Pubitemid 29517569)
4. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM et al (2006). Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295: 2003-2017. (Pubitemid 44794003)
5. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H et al (2008). An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 65: 135-144. (Pubitemid 351222547)
6. Arias A, Feinn R, Kranzler HR (2006). Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend 83: 262-268.
7. Balldin J, Berglund M, Borg S, Mansson M, Bendtsen P, Franck J et al (2003). A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 27: 1142-1149. (Pubitemid 36890391)
8. Bart G, Kreek MJ, Ott J, LaForge KS, Proudnikov D, Pollak L et al (2005). Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 30: 417-422. (Pubitemid 40129493)
9. Bergen AW, Kokoszka J, Peterson R, Long JC, Virkkunen M, Linnoila M et al (1997). Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry 2: 490-494.
10. Bohn MJ, Krahn DD, Staehler BA (1995). Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res 19: 600-606.
11. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L et al (1998). Single-nucleotide polymorphism in the human muopioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 95: 9608-9613. (Pubitemid 28506279)
12. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R et al (2000). A multicentre, randomized, double-blind, placebocontrolled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 35: 587-593.
13. Cho MJ, Chang SM, Hahm BJ, Chung IW, Bae A, Lee YM et al (2011). Lifetime risk and age of onset distributions of psychiatric disorders: analysis of national sample survey in South Korea. Soc Psychiatry Psychiatr Epidemiol. (in press)
14. Crowley JJ, Oslin DW, Patkar AA, Gottheil E, DeMaria Jr PA, O'Brien CP et al (2003). A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr Genet 13: 169-173. (Pubitemid 37082977)
15. Davidson D, Swift R, Fitz E (1996). Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res 20: 732-739. (Pubitemid 26186942)
16. Del Boca FK, Kranzler HR, Brown J, Korner PF (1996). Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin Exp Res 20: 1412-1417. (Pubitemid 26393943)
17. Drobes DJ, Anton RF, Thomas SE, Voronin K (2004). Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res 28: 1362-1370. (Pubitemid 39238295)
18. Ducat E, Ray B, Bart G, Umemura Y, Varon J, Ho A et al (2011). Mu-opioid receptor A118G polymorphism in healthy volunteers affects hypothalamic- pituitary-adrenal axis adrenocorticotropic hormone stress response to metyrapone. Addict Biol. (in press)
19. Eng MY, Luczak SE, Wall TL (2007). ALDH2, ADH1B, and ADH1C genotypes in Asians: a literature review. Alcohol Res Health 30: 22-27.
20. Erblich J, Earleywine M (1995). Distraction does not impair memory during intoxication: support for the attention-allocation model. J Stud Alcohol 56: 444-448.
21. Erickson CK (1996). Review of neurotransmitters and their role in alcoholism treatment. Alcohol Alcohol Suppl 1: 5-11. (Pubitemid 26150739)
22. Filbey FM, Ray L, Smolen A, Claus ED, Audette A, Hutchison KE (2008). Differential neural response to alcohol priming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotypes. Alcohol Clin Exp Res 32: 1113-1123.
23. Fisher RA (1922). On the interpretation of x(2) from contingency tables, and the calculation of P. J R Statist Soc 85: 87-94.
24. Franke P, Wang T, Nothen MM, Knapp M, Neidt H, Albrecht S et al (2001). Nonreplication of association between mu-opioidreceptor gene (OPRM1) A118G polymorphism and substance dependence. Am J Med Genet 105: 114-119.
25. Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R et al (2007). Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res 31: 555-563. (Pubitemid 46434892)
26. Gelernter J, Kranzler H, Cubells J (1999). Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol-and drugdependent subjects. Mol Psychiatry 4: 476-483. (Pubitemid 29497736)
27. Goldman D, Oroszi G, O'Malley S, Anton R (2005). COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms. J Stud Alcohol (Suppl 15): 56-64. (Pubitemid 41193177)
28. Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramirez M et al (2002). A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res 26: 1381-1387.
29. Guo WJ, Xu XF, Lee S (2009). More alcohol dependence than abuse in rural China. Addiction 104: 2118-2119.
30. Hao W, Chen H, Su Z (2005). China: alcohol today. Addiction 100: 737-741. (Pubitemid 40769817)
31. Heinala P, Alho H, Kiianmaa K, Lonnqvist J, Kuoppasalmi K, Sinclair JD (2001). Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol 21: 287-292. (Pubitemid 32452933)
32. Hernandez-Avila CA, Covault J, Wand G, Zhang H, Gelernter J, Kranzler HR (2007). Population-specific effects of the Asn40Asp polymorphism at the mu-opioid receptor gene (OPRM1) on HPA-axis activation. Pharmacogenet Genomics 17: 1031-1038. (Pubitemid 351339487)
33. Hernandez-Avila CA, Wand G, Luo X, Gelernter J, Kranzler HR (2003). Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet B 118B: 60-65. (Pubitemid 37064077)
34. Herz A (1997). Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl) 129: 99-111. (Pubitemid 27033665)
35. Higuchi S, Matsushita S, Maesato H, Osaki Y (2007). Japan: alcohol today. Addiction 102: 1849-1862. (Pubitemid 350145661)
36. Jacobson AF, Goldstein BJ, Dominguez RA, Steinbook RM (1986). Interrater agreement and intraclass reliability measures of SAFTEE in psychopharmacologic clinical trials. Psychopharmacol Bull 22: 382-388. (Pubitemid 16043809)
37. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R et al (2003). Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebocontrolled study. Arch Gen Psychiatry 60: 92-99. (Pubitemid 36070869)
38. Killeen TK, Brady KT, Gold PB, Simpson KN, Faldowski RA, Tyson C et al (2004). Effectiveness of naltrexone in a community treatment program. Alcohol Clin Exp Res 28: 1710-1717. (Pubitemid 39551832)
39. Kim SG, Kim CM, Choi SW, Jae YM, Lee HG, Son BK et al (2009). A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcoholdependent patients. Psychopharmacology (Berl) 201: 611-618.
40. King AC, de Wit H, McNamara PJ, Cao D (2011). Rewarding, stimulant, and sedative alcohol responses and relationship to future binge drinking. Arch Gen Psychiatry 68: 389-399.
41. King AC, Volpicelli JR, Frazer A, O'Brien CP (1997). Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl) 129: 15-22. (Pubitemid 27037445)
42. Kranzler HR, Gelernter J, O'Malley S, Hernandez-Avila CA, Kaufman D (1998). Association of alcohol or other drug dependence with alleles of the mu opioid receptor gene (OPRM1). Alcohol Clin Exp Res 22: 1359-1362. (Pubitemid 28443161)
43. Kranzler HR, Modesto-Lowe V, Van Kirk J (2000). Naltrexone vs nefazodone for treatment of alcohol dependence. A placebocontrolled trial. Neuropsychopharmacology 22: 493-503. (Pubitemid 30145617)
44. Kreek MJ (1996). Opiates, opioids and addiction. Mol Psychiatry 1: 232-254. (Pubitemid 126441297)
45. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA (2001). Naltrexone in the treatment of alcohol dependence. N Engl J Med 345: 1734-1739.
46. Latt NC, Jurd S, Houseman J, Wutzke SE (2002). Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust 176: 530-534. (Pubitemid 34649401)
47. Levine J, Schooler NR (1986). SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 22: 343-381. (Pubitemid 16043808)
48. Li TK, Yin SJ, Crabb DW, O'Connor S, Ramchandani VA (2001). Genetic and environmental influences on alcohol metabolism in humans. Alcohol Clin Exp Res 25: 136-144. (Pubitemid 32147705)
49. Littleton J, Zieglgansberger W (2003). Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict 12(Suppl 1): S3-11. (Pubitemid 36583412)
50. Loh el W, Fann CS, Chang YT, Chang CJ, Cheng AT (2004). Endogenous opioid receptor genes and alcohol dependence among Taiwanese Han. Alcohol Clin Exp Res 28: 15-19. (Pubitemid 38114019)
51. Luo X, Kranzler HR, Zhao H, Gelernter J (2003). Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. Am J Med Genet B 120B: 97-108. (Pubitemid 37059385)
52. MacKillop J (2006). Factor structure of the alcohol urge questionnaire under neutral conditions and during a cue-elicited urge state. Alcohol Clin Exp Res 30: 1315-1321. (Pubitemid 44114682)
53. Martin CS, Earleywine M, Musty RE, Perrine MW, Swift RM (1993). Development and validation of the biphasic alcohol effects scale. Alcohol Clin Exp Res 17: 140-146. (Pubitemid 23080981)
54. McCaul ME, Wand GS, Stauffer R, Lee SM, Rohde CA (2001). Naltrexone dampens ethanol-induced cardiovascular and hypothalamic-pituitary-adrenal axis activation. Neuropsychopharmacology 25: 537-547. (Pubitemid 32830958)
55. Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O'Brien CP et al (2001). Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 10: 258-268. (Pubitemid 32879092)
56. Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI et al (2001). Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 25: 1634-1647. (Pubitemid 33104926)
57. Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E (2001). Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 96: 1565-1573.
58. O'Connor S, Morzorati S, Christian J, Li TK (1998). Clamping breath alcohol concentration reduces experimental variance: application to the study of acute tolerance to alcohol and alcohol elimination rate. Alcohol Clin Exp Res 22: 202-210. (Pubitemid 28139218)
59. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992). Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 49: 881-887.
60. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002). Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary- adrenocortical axis. Psychopharmacology (Berl) 160: 19-29. (Pubitemid 34169822)
61. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR et al (2003). A functional polymorphism of the muopioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28: 1546-1552. (Pubitemid 41070891)
62. Ramchandani VA, Bolane J, Li TK, O'Connor S (1999). A physiologically-based pharmacokinetic (PBPK) model for alcohol facilitates rapid BrAC clamping. Alcohol Clin Exp Res 23: 617-623. (Pubitemid 29203217)
63. Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H et al (2011). A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry 16: 809-817.
64. Ray LA, Hutchison KE (2004). A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 28: 1789-1795. (Pubitemid 39665194)
65. Ray LA, Hutchison KE (2007a). Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry 64: 1069-1077. (Pubitemid 47360852)
66. Ray LA, Hutchison KE, Ashenhurst JR, Morrow AL (2010a). Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the ASP40 allele of the OPRM1 gene: a pilot investigation. Alcohol Clin Exp Res 34: 1479-1487.
67. Ray LA, Mackillop J, Leggio L, Morgan M, Hutchison KE (2009a). Effects of naltrexone on cortisol levels in heavy drinkers. Pharmacol Biochem Behav 91: 489-494.
68. Ray LA, MacKillop J, Leventhal A, Hutchison KE (2009b). Catching the alcohol buzz: an examination of the latent factor structure of subjective intoxication. Alcohol Clin Exp Res 33: 2154-2161.
69. Ray LA, Meskew-Stacer S, Hutchison KE (2007b). The relationship between prospective self-rating of alcohol sensitivity and craving and experimental results from two alcohol challenge studies. J Stud Alcohol Drugs 68: 379-384.
70. Ray LA, Miranda Jr R, Tidey JW, McGeary JE, MacKillop J, Gwaltney CJ et al (2010b). Polymorphisms of the mu-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment. J Abnorm Psychol 119: 115-125.
71. Rubio G, Manzanares J, Lopez-Munoz F, Alamo C, Ponce G, Jimenez-Arriero MA et al (2002). Naltrexone improves outcome of a controlled drinking program. J Subst Abuse Treat 23: 361-366. (Pubitemid 35477815)
72. Schinka JA, Town T, Abdullah L, Crawford FC, Ordorica PI, Francis E et al (2002). A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances. Mol Psychiatry 7: 224-228. (Pubitemid 34177793)
73. Schuckit MA (1984). Subjective responses to alcohol in sons of alcoholics and control subjects. Arch Gen Psychiatry 41: 879-884. (Pubitemid 14026548)
74. Setiawan E, Pihl RO, Cox SM, Gianoulakis C, Palmour RM, Benkelfat C et al (2011). The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype. Alcohol Clin Exp Res 35: 1134-1141.
75. Shi J, Hui L, Xu Y, Wang F, Huang W, Hu G (2002). Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum Mutat 19: 459-460.
76. Singer JD (1998). Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. J Educ Behav Statist 24: 323-355. (Pubitemid 128474255)
77. Sobell MB, Sobell LC, Klajner F, Pavan D, Basian E (1986). The reliability of a timeline method for assessing normal drinker college students' recent drinking history: utility for alcohol research. Addict Behav 11: 149-161. (Pubitemid 16039844)
78. Swift RM, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H (1994). Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 151: 1463-1467. (Pubitemid 24301690)
79. Tan EC, Tan CH, Karupathivan U, Yap EP (2003). Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations. NeuroReport 14: 569-572. (Pubitemid 36528992)
80. Tate SK, Goldstein DB (2004). Will tomorrow's medicines work for everyone? Nat Genet 36(Suppl): S34-S42. (Pubitemid 41103836)
81. Tidey JW, Monti PM, Rohsenow DJ, Gwaltney CJ, Miranda Jr R., McGeary JE et al (2008). Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res 32: 58-66. (Pubitemid 350293891)
82. Town T, Abdullah L, Crawford F, Schinka J, Ordorica PI, Francis E et al (1999). Association of a functional mu-opioid receptor allele (+118A) with alcohol dependency. Am J Med Genet 88: 458-461. (Pubitemid 29485067)
83. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992). Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876-880.
84. Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP (1995). Effect of naltrexone on alcohol 'high' in alcoholics. Am J Psychiatry 152: 613-615.
85. Wall TL, Thomasson HR, Schuckit MA, Ehlers CL (1992). Subjective feelings of alcohol intoxication in Asians with genetic variations of ALDH2 alleles. Alcohol Clin Exp Res 16: 991-995.
86. Wand GS, McCaul M, Yang X, Reynolds J, Gotjen D, Lee S et al (2002). The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 26: 106-114. (Pubitemid 34075281)
87. White HR, Labouvie EW (1989). Towards the assessment of adolescent problem drinking. J Stud Alcohol 50: 30-37. (Pubitemid 19066883)
88. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W (2005). Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280: 32618-32624. (Pubitemid 41368304)